Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice

International Journal of Antimicrobial Agents

Volumn 43, Issue 2, 2014, Pages 148-153

  Zhao, Weijie ^a   Guo, Zhenyong ^a   Zheng, Meiqin ^a   Zhang, Jinfu ^a   Wang, Bin ^a   Li, Peng ^a   Fu, Lei ^a   Liu, Shuo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Activity; Combination regimen; Cytokine; Extensively drug resistant tuberculosis; Linezolid; Multidrug resistant tuberculosis

Indexed keywords

ACTIVITY; COMBINATION REGIMEN; CYTOKINE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; LINEZOLID; MULTIDRUG-RESISTANT TUBERCULOSIS;

ACETAMIDES; ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; LUNG; MALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84893681944     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.10.010     Document Type: Article

References (29)

1. World Health Organization Global tuberculosis report 2012 WHO Geneva, Switzerland http://apps.who.int/iris/handle/10665/75938 [accessed 4.11.13].
2. C.L. Daley, and J.A. Caminero Management of multidrug resistant tuberculosis Semin Respir Crit Care Med 34 2013 44 59
3. D.E. Snider, D.L. Cohn, P.T. Davidson, E.S. Hershfield, and M.H. Smith Standard therapy for tuberculosis Chest 87 1985 S117 S124
4. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis 2006 WHO Geneva, Switzerland
5. C. Jagannath, M.R. Emanuele, and R.L. Hunter Activity of poloxamer CRL-1072 against drug-sensitive and resistant strains of Mycobacterium tuberculosis in macrophages and in mice Int J Antimicrob Agents 15 2000 55 63
6. S. Ermertcan, M. Hosgor-Limoncu, B. Erac, H. Tasli, C. Cavusoglu, and H. Bozkurt In vitro activity of linezolid against Mycobacterial tuberculosis strains isolated from Western Turkey Jpn J Infect Dis 62 2009 384 385
7. G. Sotgiu, R. Centis, L. D'Ambrosio, J.W. Alffenaar, H.A. Anger, and J.A. Caminero et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Eur Respir J 40 2012 1430 1442
8. K.C. Chang, W.W. Yew, S.W. Cheung, C.C. Leung, C.M. Tam, and C.H. Chau et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother 57 2013 3445 3449
9. H. Cox, and N. Ford Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis Int J Tuberc Lung Dis 16 2012 447 454
10. P.S. Redford, A. Boonstra, S. Read, J. Pitt, C. Graham, and E. Stavropoulos et al. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung Eur J Immunol 40 2010 2200 2210
11. Y. Kobashi, K. Mouri, S. Yagi, Y. Obase, N. Miyashita, and M. Oka Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment J Infect 58 2009 197 204
12. S. Bertholet, D.J. Horne, E.M. Laughlin, M. Savlov, I. Tucakovic, and R.N. Coler et al. Effect of chemotherapy on whole-blood cytokine responses to Mycobacterium tuberculosis antigens in a small cohort of patients with pulmonary tuberculosis Clin Vaccine Immunol 18 2011 1378 1386
13. L. Collins, and S.G. Franzblau Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob Agents Chemother 41 1997 1004 1009
14. K. Williams, A. Minkowski, O. Amoabeng, C.A. Peloquin, D. Taylor, and K. Andries et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis Antimicrob Agents Chemother 56 2012 3114 3120
15. R. Tasneen, S.Y. Li, C.A. Peloquin, D. Taylor, K.N. Williams, and K. Andries et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis Antimicrob Agents Chemother 55 2011 5485 5492
16. N. Veziris, C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo Antimicrob Agents Chemother 47 2003 3117 3122
17. A. Vultaggio, F. Nencini, S. Pratesi, L. Maggi, A. Guarna, and F. Annunziato et al. The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10-inducing cytokines J Immunol 186 2011 4707 4715
18. D.J. Horne, S.E. Royce, L. Gooze, M. Narita, P.C. Hopewell, and P. Nahid et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis Lancet Infect Dis 10 2010 387 394
19. R. Hussain, N. Talat, F. Shahid, and G. Dawood Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development Clin Vaccine Immunol 14 2007 1578 1586
20. K.H. Skolimowska, M.X. Rangaka, G. Meintjes, D.J. Pepper, R. Seldon, and K. Matthews et al. Altered ratio of IFN-γ/IL-10 in patients with drug resistant Mycobacterium tuberculosis and HIV-tuberculosis immune reconstitution inflammatory syndrome PLoS One 7 2012 e46481
21. 4+ T cell counts have impaired Th1 responses J Immunol 158 1997 492 500
22. J. Vekemans, C. Lienhardt, J.S. Sillah, J.G. Wheeler, G.P. Lahai, and M.T. Doherty et al. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia Infect Immun 69 2001 6554 6557
23. B.A. Wu-Hsieh, C.K. Chen, J.H. Chang, S.Y. Lai, C.H. Wu, and W.C. Cheng et al. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis Clin Infect Dis 33 2001 1336 1340
24. C.T. Fiske, A.S. de Almeida, A.K. Shintani, S.A. Kalams, and T.R. Sterling Abnormal immune responses in persons with previous extrapulmonary tuberculosis in an in vitro model that simulates in vivo infection with Mycobacterium tuberculosis Clin Vaccine Immunol 19 2012 1142 1149
25. M. Lee, J. Lee, M.W. Carroll, H. Choi, S. Min, and T. Song et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis N Engl J Med 367 2012 1508 1518
26. H.A. Anger, F. Dworkin, S. Sharma, S.S. Munsiff, D.M. Nilsen, and S.D. Ahuja Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06 J Antimicrob Chemother 65 2010 775 783
27. H.S. Nam, W.J. Koh, O.J. Kwon, S.N. Cho, and T.S. Shim Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis Int J Antimicrob Agents 33 2009 92 93
28. W.J. Koh, O.J. Kwon, H. Gwak, J.W. Chung, S.N. Cho, and W.S. Kim et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis J Antimicrob Chemother 64 2009 388 391
29. G.F. Schecter, C. Scott, L. True, A. Raftery, J. Flood, and S. Mase Linezolid in the treatment of multidrug-resistant tuberculosis Clin Infect Dis 50 2010 49 55